<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04495309</url>
  </required_header>
  <id_info>
    <org_study_id>ARO-2015-1</org_study_id>
    <nct_id>NCT04495309</nct_id>
  </id_info>
  <brief_title>Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer</brief_title>
  <acronym>OLIGOMA</acronym>
  <official_title>Effectiveness and Tolerability of Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer: A Randomized Controlled Multinational and Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prognosis for patients with metastatic breast cancer has improved continuously. Systemic&#xD;
      therapies alone are not able to cure the disease permanently.&#xD;
&#xD;
      Investigators initiated this randomized controlled multinational and multicenter clinical&#xD;
      trial to analyse the impact of a local metastases-directed radiotherapy in addition to&#xD;
      standard systemic therapy in patients with oligometastatic breast cancer on progression-free&#xD;
      survival and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preferably ablative radiotherapy (radiosurgery, stereotactic radiotherapy, hypofractionated&#xD;
      image-guided radiotherapy (IGRT)) with few high-dose fractions. Larger lesions or lesions&#xD;
      with critical normal tissue involvement should be treated with three-dimensional conformal&#xD;
      radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) in moderate&#xD;
      hypofractionated radiotherapy (depending on the size and location of the target volume and&#xD;
      the decision of the radiooncologist). For critical organs in the target volume, standard&#xD;
      fractionated radiotherapy can be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First co-primary outcome measure is progression-free survival (PFS)</measure>
    <time_frame>at least 12 months after randomization</time_frame>
    <description>Co-primary progression-free survival (PFS) according to Response Evaluation Criteria In Solid Tumors (RECIST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Second co-primary outcome measure is quality of life</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Co-primary quality of life according to European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer patients with 30 items (QLQ-C30) sum score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility (per-protocol within intention-to-treat)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of participants treated per protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at least 1, up to 5 years</time_frame>
    <description>Time between randomization and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (number and degree of reported toxicities in both treatment arms)</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>Proportion of participants with degree of toxicities as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) and by Radiation Treatment Oncology Group (RTOG) by point in time of follow-up with higher degree indicating higher intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neoplasia-specific quality of life</measure>
    <time_frame>quarterly up to 5 years</time_frame>
    <description>Research and Treatment of Cancer (EORTC) Quality of Life Questionaire for Cancer patients with 30 items (QLQ-C30) with different scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer-specific quality of life</measure>
    <time_frame>quarterly up to 5 years</time_frame>
    <description>Research and Treatment of Cancer (EORTC) Quality of Life Questionaire for breast cancer patients with 23 items (QLQ-BR23) on 4-point Likert scales with different directions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Research and Treatment of Cancer (EORTC) Patient satisfaction questionnaire for cancer patients with 33 items (PATSAT-C33) on 5-point Likert scale with higher scores indicating greater satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>0 to 5 years</time_frame>
    <description>Number of patients with adverse and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">564</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care, i. e. no local radiotherapy in addition to standard systemic therapy (exception: palliative local treatment of symptomatic lesions where indicated)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care (standard systemic therapy) + study intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Metastases-directed Radiotherapy</intervention_name>
    <description>Ablative radiotherapy (radiosurgery, stereotactic radiotherapy, hypofractionated image-guided radiotherapy (IGRT)) with few high-dose fractions</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastasized breast cancer - up to 5 clinically manifest (new, progressive,&#xD;
             persistent) metastases (a lymph node metastasis and a circumscribed local recurrence&#xD;
             are each considered as one metastasis, i.e. also locoregional recurrent breast&#xD;
             carcinomas with additional hematogenic metastasis possible)&#xD;
&#xD;
          -  maximum of 3 cerebral metastases known&#xD;
&#xD;
          -  indication for palliative drug therapy (endocrine therapy and/or chemotherapy and/or&#xD;
             treatment with other substances) given according to guidelines (1st-line or further&#xD;
             therapy lines, a special regime is not specified)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2&#xD;
&#xD;
          -  local radiation of all metastases possible&#xD;
&#xD;
          -  presentation of a written declaration of consent&#xD;
&#xD;
          -  patient ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radiotherapy, if this interferes with treatment within the scope of the study&#xD;
&#xD;
          -  symptomatic metastases requiring local therapy of all metastases (e.g. pain&#xD;
             radiation), a radiation indication (or other local therapy) for individual metastases&#xD;
             is not a criterion for exclusion&#xD;
&#xD;
          -  known central nervous system (CNS) metastasis without extracerebral metastasis (in&#xD;
             these cases, immediate local therapy is mandatory)&#xD;
&#xD;
          -  more than three known CNS metastases (no indication for purely local therapy of only&#xD;
             the metastases, primary whole brain radiation is indicated)&#xD;
&#xD;
          -  multifocal metastasis in one organ with impossibility to comply with the dose&#xD;
             constraints for this organ (e.g., no indication for local therapy of only the&#xD;
             metastases, primary whole brain radiation is indicated) (e.g. in the liver)&#xD;
&#xD;
          -  exclusively regional lymph node metastasis without haematogenic metastases (in these&#xD;
             cases local therapy is clearly indicated according to guidelines)&#xD;
&#xD;
          -  relevant comorbidity, if this results in restrictions for further therapy&#xD;
&#xD;
          -  Incapacity to contract or lack of informed consent&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients with oligometastatic breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen Dunst, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathrin Dellas, Professor</last_name>
    <phone>0431/500/26570</phone>
    <email>Kathrin.Dellas@uksh.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim Klinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Sperk, MD</last_name>
      <phone>0049/621 383 4241</phone>
      <email>elena.sperk@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis für Strahlentherapie und Radioonkologie am Krankenhaus Weilheim</name>
      <address>
        <city>Weilheim</city>
        <state>Bayern</state>
        <zip>82362</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Panzer, MD</last_name>
      <phone>0049/88192452340</phone>
      <email>mpa@strahlentherapie-weilheim.de</email>
    </contact>
    <contact_backup>
      <last_name>Michaela Riepl, MD</last_name>
      <phone>0049/88192452340</phone>
      <email>mrp@strahlentherapie-weilheim.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH Klinik für Strahlentherapie/Radioonkologie</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <state>Brandenburg</state>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard E. Wurm, MD</last_name>
      <phone>0049/335 548 4721</phone>
      <email>reinhard.wurm@klinikumffo.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg Klinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilke Vorwerk, Prof.</last_name>
      <phone>0049/6421 58 66270</phone>
      <email>hilke.vorwerk@med.uni-marburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GSR Hameln im Sana Klinikum Hameln-Pyrmont</name>
      <address>
        <city>Hameln</city>
        <state>Niedersachsen</state>
        <zip>31785</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Janssen, MD</last_name>
      <phone>0049/5151 9626320</phone>
      <email>stefan.janssen@strahlentherapie.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Strahlentherapie</name>
      <address>
        <city>Hildesheim</city>
        <state>Niedersachsen</state>
        <zip>31135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susann Popella, MD</last_name>
      <phone>0049/5121 8942 913</phone>
      <email>spopella@strahlentherapie-hildesheim.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ WOB GmbH Strahlentherapie</name>
      <address>
        <city>Wolfsburg</city>
        <state>Niedersachsen</state>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel Ott, MD</last_name>
      <phone>0049/5361 803850</phone>
      <email>Marcel.Ott@Klinikum.Wolfsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strahlentherapie Bocholt Gemeinschaftspraxis und Belegabteilung am St.-Agnes-Hospital</name>
      <address>
        <city>Bocholt</city>
        <state>Nordrhein-Westfalen</state>
        <zip>46397</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eckhard Horst, MD</last_name>
      <phone>0049/2871 246540</phone>
      <email>horst@strahlentherapie-bocholt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelische Kliniken Gelsenkirchen Klinik für Strahlentherapie</name>
      <address>
        <city>Gelsenkirchen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Hepp, MD</last_name>
      <phone>0049/209 160 53001</phone>
      <email>heppdelosrios@evk-ge.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xcare Praxis für Strahlentherapie Saarlouis am Marienkrankenhaus</name>
      <address>
        <city>Saarlouis</city>
        <state>Saarland</state>
        <zip>66740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sevda Toperim</last_name>
      <phone>0049/6831 161229</phone>
      <email>sevda.toperim@x-care.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dresden, Strahlentherapie</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Schreiber, MD</last_name>
      <phone>0049/3514803500</phone>
      <email>Andreas.Schreiber@klinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Jörg Zimmer, MD</last_name>
      <phone>0049/3514803501</phone>
      <email>Zimmer-Jo@khdf.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Heinrich-Braun-Klinikum Zwickau gGmbH Klinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Zwickau</city>
        <state>Sachsen</state>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Boicev, MD</last_name>
      <phone>0049/375512802</phone>
      <email>alexander.boicev@hbk-zwickau.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christian-Albrechts-University Kiel, University Medical Center Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juergen Dunst, Prof.</last_name>
      <phone>0049/431/50026500</phone>
      <email>Juergen.Dunst@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin Dellas, Prof.</last_name>
      <phone>0049/431/50026570</phone>
      <email>Kathrin.Dellas@uksh.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Genthin-Stendal</name>
      <address>
        <city>Stendal</city>
        <zip>39576</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Weinstrauch, MD</last_name>
      <phone>0049/3931 661504</phone>
      <email>evelyn.weinstrauch@sdl.johanniter-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Sachsen-Anhalt</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligometastatic Breast Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Progression-free survival (PFS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

